Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Cosmai

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|November 26, 2023
[Ten Years of Onconephrology]Laura Cosmai
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|April 27, 2026
[Raccogliere un'eredità e aprire nuove prospettive]Laura Cosmai
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 17, 2026
[Dialisi peritoneale: perché il futuro della nefrologia passa da casa]Laura Cosmai, Loris Neri
Kidney360|May 22, 2023
High-Cutoff Hemodialysis Therapy for Patients with Light Chain Cast Nephropathy and AKI Requiring Dialysis: CommentaryLaura Cosmai, Maurizio Gallieni
Cancer|January 27, 2024
Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expectedCamillo Porta, Francesca Negri, Laura Cosmai
International Journal of Urology : Official Journal of the Japanese Urological Association|April 12, 2017
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USACamillo Porta, Laura Cosmai, Pietro Previtali
Contributions to Nephrology|February 3, 2018
Acute Kidney Injury in Cancer PatientsMaurizio Gallieni, Laura Cosmai, Camillo Porta
Current Opinion in Urology|March 20, 2021
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?Camillo Porta, Laura Cosmai, Mimma Rizzo
Journal of Nephrology|September 6, 2015
Renal toxicity of anticancer agents targeting HER2 and EGFRLaura Cosmai, Maurizio Gallieni, Camillo Porta
Future Oncology (London, England)|April 7, 2022
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterationsAndrea Franza, Marta Pirovano, Patrizia Giannatempo, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|November 26, 2023
[Ten Years of Onconephrology]Laura Cosmai
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|April 27, 2026
[Raccogliere un'eredità e aprire nuove prospettive]Laura Cosmai
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 17, 2026
[Dialisi peritoneale: perché il futuro della nefrologia passa da casa]Laura Cosmai, Loris Neri
Kidney360|May 22, 2023
High-Cutoff Hemodialysis Therapy for Patients with Light Chain Cast Nephropathy and AKI Requiring Dialysis: CommentaryLaura Cosmai, Maurizio Gallieni
Cancer|January 27, 2024
Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expectedCamillo Porta, Francesca Negri, Laura Cosmai
International Journal of Urology : Official Journal of the Japanese Urological Association|April 12, 2017
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USACamillo Porta, Laura Cosmai, Pietro Previtali
Contributions to Nephrology|February 3, 2018
Acute Kidney Injury in Cancer PatientsMaurizio Gallieni, Laura Cosmai, Camillo Porta
Current Opinion in Urology|March 20, 2021
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?Camillo Porta, Laura Cosmai, Mimma Rizzo
Journal of Nephrology|September 6, 2015
Renal toxicity of anticancer agents targeting HER2 and EGFRLaura Cosmai, Maurizio Gallieni, Camillo Porta
Future Oncology (London, England)|April 7, 2022
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterationsAndrea Franza, Marta Pirovano, Patrizia Giannatempo, et al.
Pageof 8